Related Experiment Video
Updated: Jan 12, 2026

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
7,8-Dihydroxyflavone protects acetaminophen induced liver injury through activating PI3K/Akt/NRF2/GPX4 mediated
Xintong Pei1, Rong Mu2, Siyi Liu3
1Department of Obstetrics and Gynecology, Chongqing Health Center for Women and Children (Women and Children's Hospital of Chongqing Medical University), Chongqing, 401147, China; NHC Key Laboratory of Birth Defects and Reproductive Health, Chongqing, 401147, China; Chongqing Municipal Health Commission Key Laboratory of Perinatal Medicine, Chongqing, 401147, China.
Abstract:
Acetaminophen (APAP)-induced liver injury remains a leading cause of acute liver failure, with limited therapeutic options beyond the narrow therapeutic window of N-acetylcysteine. Emerging evidence highlights ferroptosis as a critical mediator of APAP hepatotoxicity. Here, we investigated the hepatoprotective effects of 7,8-dihydroxyflavone (7,8-DHF), a natural flavonoid with antioxidative properties, against APAP-induced liver injury and explored its underlying mechanisms. In a murine model of APAP overdose, 7,8-DHF administration significantly attenuated liver damage, as evidenced by reduced serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) levels, preserved histological integrity, and suppressed oxidative stress, evidenced by a rescue of APAP-induced 4-hydroxynonenal and malondialdehyde level. Transcriptomic analyses revealed that 7,8-DHF reversed APAP-induced dysregulation of lipid metabolism and reactive oxygen species (ROS) pathways. Mechanistically, 7,8-DHF promoted nuclear translocation of NRF2, upregulated GPX4 and SLC7A11 expression, and inhibited ferroptosis-associated factors (PTGS2, ACSL4). Pharmacological inhibition of PI3K/Akt or NRF2 abrogated 7,8-DHF-mediated ferroptosis suppression and hepatoprotection in vitro and in vivo. Collectively, our findings identify 7,8-DHF as a promising therapeutic agent for APAP-induced liver injury through modulation of the PI3K/Akt/NRF2/GPX4 axis, offering a novel strategy to target ferroptosis in drug-induced liver injury.
